Silvant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Silvant Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.71M	Buy	20,606 +333	+2%	+$44.2K	0.09%	120
2025 Q4	$2.88M	Buy	20,273 +326	+2%	+$47.2K	0.1%	114
2025 Q3	$2.8M	Sell	19,947 -1,886	-9%	-$256K	0.1%	113
2025 Q2	$2.74M	Hold	21,833	–	–	0.1%	113
2025 Q1	$2.41M	Hold	21,833	–	–	0.11%	112
2024 Q4	$2.98M	Hold	21,833	–	–	0.12%	103
2024 Q3	$2.52M	Hold	21,833	–	–	0.11%	112
2024 Q2	$3.01M	Buy	21,833 +3,539	+19%	+$485K	0.13%	100
2024 Q1	$2.52M	Hold	18,294	–	–	0.12%	105
2023 Q4	$2.41M	Hold	18,294	–	–	0.13%	103
2023 Q3	$2.06M	Hold	18,294	–	–	0.12%	105
2023 Q2	$1.73M	Hold	18,294	–	–	0.1%	119
2023 Q1	$1.85M	Hold	18,294	–	–	0.12%	109
2022 Q4	$2.19M	Buy	+18,294	New	+$2.14M	0.15%	106
2019 Q2	–	Sell	-3,038	Closed	-$268K	–	340
2019 Q1	$268K	Hold	3,038	–	–	0.05%	164
2018 Q4	$217K	Sell	3,038 -995	-25%	-$95.3K	0.04%	169
2018 Q3	$496K	Hold	4,033	–	–	0.06%	126
2018 Q2	$396K	Hold	4,033	–	–	0.05%	136
2018 Q1	$334K	Buy	+4,033	New	+$341K	0.04%	156

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silvant Capital Management's NBIX Position: Q1 2026 in Review

Silvant Capital Management increased its Neurocrine Biosciences (NBIX) stake by 1.6% in Q1 2026, buying an estimated $44.2K and bringing the position to 20,606 shares worth $2.71M. The position accounts for 0.09% of the portfolio, ranked #120.

Silvant Capital Management first reported a position in NBIX in Q1 2018 and has held it in 19 quarters since. The position peaked at $3.01M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Silvant Capital Management held 20,606 shares of Neurocrine Biosciences worth $2.71M as of Q1 2026.
Silvant Capital Management bought 333 Neurocrine Biosciences shares in Q1 2026, an estimated $44.2K.
Neurocrine Biosciences made up 0.09% of Silvant Capital Management's portfolio in Q1 2026, its #120 holding.
Silvant Capital Management first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 19 quarters since.
Silvant Capital Management's Neurocrine Biosciences position peaked at $3.01M in Q2 2024.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Silvant Capital Management's 13F filing for Q1 2026, filed 14 May 2026.